In a filing, Veracyte Inc revealed its Director EASTHAM KARIN unloaded Company’s shares for reported $0.91 million on Dec 05 ’25. In the deal valued at $45.45 per share,20,000 shares were sold. As a result of this transaction, EASTHAM KARIN now holds 13,554 shares worth roughly $0.6 million.
Then, KARIN EASTHAM bought 20,000 shares, generating $948,200 in total proceeds.
Before that, McGuire Annie sold 1,422 shares. Veracyte Inc shares valued at $67,261 were divested by the SVP, General Counsel at a price of $47.30 per share. As a result of the transaction, McGuire Annie now holds 78,499 shares, worth roughly $3.48 million.
A number of analysts have revised their coverage, including Canaccord Genuity’s analysts, who began to cover the stock in mid October with a ‘”a Hold”‘ rating. Craig Hallum began covering VCYT with “Buy” recommendation on March 20, 2025. Goldman revised its rating on December 05, 2024. It rated VCYT as “a Neutral” which previously was an “a Buy”.
Price Performance Review of VCYT
On Monday, Veracyte Inc [NASDAQ:VCYT] saw its stock fall -0.56% to $44.36. Over the last five days, the stock has lost -4.38%. Veracyte Inc shares have risen nearly 0.61% since the year began. Nevertheless, the stocks have risen 12.02% over the past one year. While a 52-week high of $50.71 was reached on 11/25/25, a 52-week low of $22.61 was recorded on 07/18/25.
Levels Of Support And Resistance For VCYT Stock
The 24-hour chart illustrates a support level at 43.49, which if violated will result in even more drops to 42.61. On the upside, there is a resistance level at 45.10. A further resistance level may holdings at 45.83.
How much short interest is there in Veracyte Inc?
A steep rise in short interest was recorded in Veracyte Inc stocks on 2025-11-14, dropping by -1.27 million shares to a total of 5.45 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 6.72 million shares. There was a decline of -23.35%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 15, 2024 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $50 price target.
